• PIPELINE
• COMPANY
  • About us
  • Team
    • management team filip fratev
    • management team dimitar dimitrov
    • management team elina mihaylova
    • management team miguel rivera
  • Partners
  • Business model
  • Careers
  • Contact us
• NEWS & PUBLICATIONS
  • Company news
    • Micar 21 Ltd started to provide to customers discovery of novel active substances for medicinal cosmetics development.
    • New! A pioneering study focused on the prevention of hypertrophic cardiomyopathy (HCM) among individuals with a sarcomere gene mutation (Feb. 2015)
    • Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
    • Structural and Dynamical Insight into PPARγ
    • Try our outsourcing services!
    • Identification of P-glycoprotein binders based on in house prepared diverse set of structures
    • PPARγ helix 12 exhibits an antagonist conformation
    • PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
    • Micar Innovation (Micar21) TOP 8 BioTech Award by Delta Ventures and the TOP 50 of the 2018 Startup World Cup & Summit Regional Finals!
    • Diplomatic World
    • Micar Innovation listed as a Emerging Players
    • Micar Innovation is One of 250 Companies
    • Micar Innovation (Micar21) is the winner of а prestigious award for Innovative enterprise of the year 2018
    • AI for Drug Discovery Biomarker Development
    • Discovery of the first class of dual CCR5/7 antagonists for COVID-19
    • Covid B.1.1.529
  • Scientific publications
    • Combination of Genetic Screening and Molecular Dynamics as a Useful Tool for Identification of Disease-Related Mutations: ZASP PDZ Domain G54S Mutation Case
    • Structural insight into the UNC-45–myosin complex
    • Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow
    • Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study
    • Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
    • Structural and Dynamical Insight into PPARγ Antagonism: In silico Study of the Ligand-Receptor Interactions of non-Covalent Antagonists
    • Molecular dynamics simulation of the human estrogen receptor alpha: contribution to the pharmacophore of the agonists
    • PPARγ helix 12 exhibits an antagonist conformation
    • PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
    • Prediction of Accurate Binding Modes using Combination of classical and accelerated Molecular dynamics and Free Energy Perturbation Calculations: An Application to Toxicity Studies
    • An Improvement of the Free Energy Perturbation (FEP+) Sampling Protocol in Case of Flexible protein Ligand Binding Sites
    • Combination of Structural based Pharmacophore and Docking Virtual Screens: An Efficient Structure-based Protocol for Lead Identification
    • Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies
    • Discovery of New Classes of Glycine transporter 2 (GlyT2) Inhibitors and GlyT2 Selectivity Studies
    • Discovery of New AKT1 Inhibitors by Combination of In silico Structure Based Virtual Screening Approaches and Biological Evaluations
    • N501Y_mutation_manuscript
    • N501Y and K417N mutation manuscript
  • Achievements & Awards
  • Interview in the news
  • Analytics reports
  • Events

Privacy Policy

updated soon